The Effect Of Lisinopril On Polycythemia

Overview

About this study

The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Hemoglobin in Men: \>16.5 g/dL (10.3 mmol/L).
* Hemoglobin in Women \>16.0 g/dL (10.0 mmol/L).
* BMI 18-40 kg/m2.

Exclusion Criteria:

* Positive JAK2 gene linked to Polycythemia Vera.
* Current smoker or previous heavy smoker (\>15 pack years) who quit less than 12 months prior to enrollment.
* Resting SpO₂ ≤ 94% on room air.
* Current or recent (within the past 6 months) use of testosterone or androgen supplementation.
* Any confounding respiratory or renal disease, including diagnosed or suspected sleep apnea, or stage 3 and up of chronic kidney disease.
* Any confounding hematologic disease that may alter hemoglobin level.
* Currently treated with ACE inhibitors.
* Currently treated with potassium-sparing diuretics.
* Currently on SGLT2 or use within 4 weeks prior to screening.
* Baseline systolic blood pressure ≤90 mmHg.
* Baseline systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg.
* Occupational exposure associated with chronically elevated COHb (auto repair, etc.).
* History of anaphylaxis or angioedema.
* Pregnant or breastfeeding.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Joyner, M.D.

Contact us for the latest status

Contact information:

Nancy Meyer

5072550913

meyer.nancy2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20601093

Mayo Clinic Footer